Table 7.
Genea | CONb | ZnMetc | SEMd | P value |
---|---|---|---|---|
AMPkα | 1.746 | 1.613 | 0.207 | 0.525 |
MHC-I | 0.649 | 1.025 | 0.166 | 0.030 |
MHC-IIA | 2.517 | 2.208 | 0.438 | 0.485 |
MHC-IIX | 1.514 | 1.085 | 0.165 | 0.013 |
β1AR | 7.163 | 3.101 | 1.457 | 0.008 |
β2AR | 0.894 | 1.282 | 0.194 | 0.053 |
β3AR | 33.133 | 41.718 | 9.752 | 0.397 |
CEBPβ | 5.670 | 4.838 | 1.157 | 0.476 |
GPR43 | 2.391 | 0.873 | 1.292 | 0.247 |
GPR41 | 38.694 | 38.257 | 16.807 | 0.979 |
Glut4 | 1.035 | 1.123 | 0.095 | 0.363 |
PPARγ | 3.020 | 1.749 | 0.540 | 0.024 |
SCD | 9.745 | 2.303 | 3.052 | 0.019 |
AMPKα AMP-activated protein kinase alpha, MHC-I myosin heavy chain-I, MHC-IIA myosin heavy chain-IIA, MHC-IIX myosin heavy chain-IIX, β1AR beta 1 adrenergic receptor, β2AR beta 2 adrenergic receptor, β3AR beta 3 adrenergic receptor, CEBPβ C-enhancer binding protein beta, GPR43 G-protein coupled receptor 43, GPR41 G-protein coupled receptor 41, Glut4 glucose transporter type 4, PPARγ peroxisome proliferator-activated receptor gamma, SCD stearoyl-CoA desaturase
aRelative abundance of the AMPKα, MHC-I, MHC-IIA, MHC-IIX, β1AR, β2AR, β3AR, CEBPβ, GPR43, GPR41, Glut4, PPARγ, and SCD genes were normalized with the RPS9 endogenous control by using the change in cycle threshold (ΔCT)
bCON: Control 90 ppm Zn added from ZnSO4 (n = 20 steers)
cZnMet: Control plus 720 mg Zn added from ZINPRO® zinc methionine (n = 20 steers)
dPooled standard error of the mean